Table 1.
Baseline characteristics of the included studies.
| Study | Region | Study design |
Number of patients | HBV DNA log 10 copies/mL |
HBeAg-positive | PTA (%) or INR (means ± SD) | TBIL (means ± SD) (%) | ALB (means ± SD) (%) | ALT (means ± SD) (%) |
Treatment duration (months) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ETV | LAM | ETV | LAM | ETV | LAM | ETV | LAM | ETV | LAM | ETV | LAM | ETV | LAM | ||||
| Hu et al., 2010 [25] | China | cohort | 90 | 90 | 8.2 ± 1 | 8.2 ± 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 6 |
|
| |||||||||||||||||
| Gao et al., 2015 [26] | China | cohort | 46 | 66 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 24 |
|
| |||||||||||||||||
| Cui et al., 2010 [22] | China | cohort | 33 | 34 | 5.9 ± 1.5 | 5.9 ± 1.5 | 10 | 13 | 2.27 ± 0.55 | 2.61 ± 1.03 | 20.10 ± 11.24 | 19.91 ± 8.56 | 33.36 ± 4.43 | 31.64 ± 5.32 | 364 (47–2861) | 226.5 (22–2314) | 3 |
|
| |||||||||||||||||
| Chen et al., 2012 [27] | China | cohort | 42 | 30 | 7.04 ± 1.6 | 7.25 ± 0.89 | NA | NA | 34.88 ± 12.27 | 32.18 ± 11.44 | 326.29 ± 201.35 | 332.65 ± 182.65 | 31.45 ± 5.79 | 29.59 ± 5.63 | 324.19 ± 310.04 | 287.61 ± 261.50 | 3 |
|
| |||||||||||||||||
| Lai et al., 2013 [28] | China | cohort | 93 | 89 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Na | NA | 3 |
|
| |||||||||||||||||
| Zhang et al., 2014 [21] | China | cohort | 65 | 54 | 7 ± 1.4 | 7.2 ± 1.6 | 21 | 23 | 24.7 ± 6.0 | 25.1 ± 5.7 | 331.6 ± 74.8 | 320.1 ± 82.4 | 28.7 ± 6.9 | 29.4 ± 5.3 | 352.5 ± 77.2 | 345.2 ± 89.5 | 13 |
|
| |||||||||||||||||
| Wen et al., 2010 [19] | China | RCT | 46 | 47 | NA | NA | NA | NA | 29.8 ± 8.5 | 30.6 ± 9.1 | 375.2 ± 200.3 | 389.4 ± 198.1 | 31.4 ± 4.6 | 32.7 ± 3.9 | 402.5 ± 292.7 | 395.8 ± 297.4 | 12 |
|
| |||||||||||||||||
| Cai and Shi, 2011 [29] | China | RCT | 38 | 34 | NA | NA | NA | NA | 34.6 ± 8.1 | 34.8 ± 9.6 | 256.5 ± 137.4 | 257.6 ± 135.9 | 31.4 ± 4.6 | 32.8 ± 4.5 | 395.4 ± 235.3 | 387.1 ± 245.4 | 12 |
|
| |||||||||||||||||
| He, 2013 [30] | China | RCT | 57 | 57 | 6.2 ± 2.1 | 6.1 ± 1.9 | NA | NA | 30 ± 8 | 30 ± 8 | 339 ± 135 | 342 ± 148 | 31 ± 6 | 31 ± 6 | 399 ± 245 | 404 ± 237 | 6 |
|
| |||||||||||||||||
| Yuan, 2015 [31] | China | RCT | 149 | 148 | NA | NA | NA | NA | 33.89 ± 7.78 | 33.96 ± 7.80 | 260.41 ± 140.11 | 260.38 ± 140.10 | 31.88 ± 6.11 | 31.89 ± 6.10 | 396.51 ± 240.12 | 397.00 ± 240.22 | 12 |
ETV: entecavir; LAM: lamivudine; NA: not available; PTA: prothrombin activity; INR: international standard ratio; TBIL: total bilirubin; ALB: albumin; ALT: alanine aminotransferase; RCT: randomized controlled studies.